ClinicalTrials.gg

Program

JNJ-89495120

A development code.

Its studies are mostly in Depressive Disorder, Major, led by Johnson & Johnson.

Furthest: phase 2, since Jan 15, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson10 open or runningphase 2since Jan 15, 2025Jan 15, 2025none ahead
  • Named in Johnson & Johnson’s own pipeline as JNJ-5120, phase 2, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2025First study: phase 2 study in Depressive Disorder, MajorFirst studyNCT06785012 · 105 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06785012Depressive Disorder, Major · United States2CompletedJun 25, 2026105

How it is read

Names in the registry

  • “JNJ-89495120”, 1 entry

Codes read as this program: JNJ89495120.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
JNJ-89495120 (Johnson & Johnson): development program | ClinicalTrials.gg